Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756480 · ClinicalTrials.gov registry record
Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance
A clinical trial of Endometriosis and Endometrial Diseases, sponsored by Johns Hopkins University.
- Active
- Registry status
- 135
- Enrollment target
- 3
- Study locations
NCT03756480: Active study of Endometriosis and Endometrial Diseases, sponsored by Johns Hopkins University.
NCT03756480 is a study of Endometriosis and Endometrial Diseases that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 135 participants, below the 261-participant average among 48 other Endometriosis trials with a reported enrollment target (48% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03756480, a study of Endometriosis and Endometrial Diseases, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- 135 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.
Primary Outcome
Digital droplet PCR will be used to identify somatic cancer-driver mutations with the presence of at least one of KRAS or ARID1A or PIK3CA or PPP2R1A cancer-driver mutations to assess any difference between progesterone-resistant endometriosis and progesterone-sensitive endometriosis.
Conditions Studied
Study Locations (3)
Connecticut
- Yale School of Medicine - New Haven
Maryland
- Johns Hopkins Hospital - Baltimore
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2026-10-01 |
What the registry record for NCT03756480 still lists
NCT03756480 is an observational study that tracks outcomes without assigning an intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 261-participant average among 48 other Endometriosis trials with a reported enrollment target (48% lower).
The record links to 2 conditions, with Endometriosis appearing as the primary indexed condition, and to 0 interventions.
NCT03756480 reports a single indexed study location in Connecticut, Maryland, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03756480 about?
NCT03756480 is a clinical study titled "Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance". This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.
What is the current status of trial NCT03756480?
This trial is currently active not recruiting. The enrollment target is 135 participants. The study started on 2020-10-01. Estimated completion is 2026-10-01.
What conditions does trial NCT03756480 study?
This clinical trial studies the following conditions: Endometriosis, Endometrial Diseases.
Who is sponsoring clinical trial NCT03756480?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03756480 being conducted?
This trial has 3 study locations across Connecticut, Maryland, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03756480's enrollment target sits among peer trials
135 15th of 48 higher than 34 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Thromboxane Function in Women With Endometriosis
RECRUITING · Phase 4
-
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
RECRUITING · NA
-
The Impact of Yoga on Endometriosis-Related Pain
RECRUITING · NA
-
Endometriosis and Microvascular Dysfunction: Role of Inflammation
RECRUITING · Early Phase 1
-
Physical Therapy After Endometriosis Excision
RECRUITING · NA
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI